


PHARMACEUTICAL 2019



## RELMADA THERAPEUTICS INC. Rank 338 of 363







PHARMACEUTICAL 2019



## RELMADA THERAPEUTICS INC. Rank 338 of 363

The relative strengths and weaknesses of RELMADA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RELMADA THERAPEUTICS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 13% points. The greatest weakness of RELMADA THERAPEUTICS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 162% points.

The company's Economic Capital Ratio, given in the ranking table, is -318%, being 355% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	2,738
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,905
Liabilities, Non-Current	0
Other Assets	298
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,656
Other Net Income	-2,043
Other Revenues	0
Property and Equipment	12
Research and Development	2,943
Selling, General and Administrative Expense	3,975

Output Variable	Value in 1000 USD
Assets	3,048
Liabilities	8,561
Expenses	6,917
Revenues	0
Stockholders Equity	-5,513
Net Income	-8,961
Comprehensive Net Income	-8,961
Economic Capital Ratio	-318%

